Story perspectives

Keytruda Sales Soar to $31.7 Billion Amid Access Issues

4/13/2026

Summary

Story summary

The cross-border investigation by DW and the International Consortium of Investigative Journalists (ICIJ) shows Merck & Co.'s Keytruda becoming a best-seller while many patients face limited access.
The report highlights how pricing, patents, and regulatory frameworks shape treatment availability.
Keytruda generated $31.7 billion in sales in 2025, with profits funneled to shareholders.
In Turkey, Keytruda costs six times the minimum wage, prompting legal action and highlighting the global access gap.

1 of 1

Story summary

The cross-border investigation by DW and the International Consortium of Investigative Journalists (ICIJ) shows Merck & Co.'s Keytruda becoming a best-seller while many patients face limited access.
The report highlights how pricing, patents, and regulatory frameworks shape treatment availability.
Keytruda generated $31.7 billion in sales in 2025, with profits funneled to shareholders.
In Turkey, Keytruda costs six times the minimum wage, prompting legal action and highlighting the global access gap.